Skip to main content
. Author manuscript; available in PMC: 2017 Jun 5.
Published in final edited form as: Curr Hematol Malig Rep. 2015 Jun;10(2):145–157. doi: 10.1007/s11899-015-0254-5

Table 1.

Comparison of Frontline Therapy Outcomes in Chronic Phase CML

Clinical Outcome (%) TOPS22
ENESTnd34
DASISION41
IM 400 (n=157) IM 800 (n=319) NIL 600 (n=282) NIL 800 (n=281) IM 400 (n=283) DAS 100 (n=259) IM 400 (n=260)
BCR-ABL <10% by 3 mo NR NR 91 89 67 84 64
BCR-ABL <10% by 6 mo NR NR 97 93 84 89 83
CCyR by 12 mo 67 70 80 78 65 83 72
MMR by 12 mo 39 45 44 43 22 46 28
Cumulative MR4.5 NR NR 40 37 23 42 33
Minimum f/u (months) 42 42 48 48 48 60 60
Still on study drug at last f/u 73 68 66 69 57 61 63
Progression-free survival 92 94 93 96 92 85 86
Overall Survival 94 94 94 97 93 91 90

CML, chronic myeloid leukemia; IM 400 or 800, imatinib total daily dose of 400 or 800 mg; NIL 600 or 800, nilotinib total daily dose of 600 or 800 mg; DAS 100, dasatinib total daily dose of 100 mg; n, number of patients randomized to the particular arm; f/u, follow-up; BCR/ABL1 transcript level in international scale(IS); CCyR (complete cytogenetic response), absence of Ph chromosome-positive metaphase; MMR (major molecular response), BCR-ABL1/ABL1 transcript ratio ≤ 0.1% (IS); MR4.5, BCR-ABL1 transcript ≤ 0.0032%